Sort
78,016 grants matching “breast cancer”
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
$644,443Jennifer R Brown · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Merging Marine-Derived Cytotoxic Natural Products With Experimental Therapeutics
$644,409Phil Crews · University Of California Santa Cruz · R01 · FY2015 · CA
Exercise as Interception Therapy in Primary High Risk Cancer
$644,390Lee W Jones · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Exercise as Interception Therapy in Primary High Risk Cancer
$644,389Lee W Jones · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Brain Tumors - Immunological and Biological Studies
$644,338Duke University · R37 · FY2005 · CA
Aim 2: Network-level modeling of single-agent and combination therapy
$644,322Peter Karl Sorger · Harvard Medical School · P50 · FY2014 · GM
Mechanisms of breast cancer associated with obesity
$644,288Charlotte Kuperwasser · Tufts University Boston · R01 · FY2012 · CA
Impact of Social contagion on Physician use of unproven cancer interventions
$644,255Cary P Gross · Yale University · R01 · FY2015 · CA
Validation of a novel 3D culture platform for TNBC treatment selection
$644,226Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2022 · CA
Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC)
$644,191Jenny C-N Chang · Methodist Hospital Research Institute · R01 · FY2023 · CA
A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors
$643,972Patricia A. Ganz · University Of California Los Angeles · R01 · FY2020 · CA
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care
$643,968Jennifer M. Yeh · Boston Children'S Hospital · R01 · FY2023 · CA
Epigenetic Regulation of Normal and Pathologic CTCF Functions by Paralogous CTCFL a.k.a. BORIS
$643,928Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Physical Activity, Sedentary Behavior, and Cancer Incidence in Women
$643,923Kelly Evenson · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
NCI National Clinical Trials Network - Lead Academic Participant Sites
$643,919Anthony D Elias · University Of Colorado Denver · UG1 · FY2019 · CA
Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children
$643,900Catherine Metayer · University Of California Berkeley · R01 · FY2021 · ES
Who Cares For Older Breast Cancer Surivors And How Does It Affect Quality?
$643,828Jeanne Mandelblatt · Georgetown University · R01 · FY2010 · CA
Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer
$643,798Ji Qiu · Arizona State University-Tempe Campus · R01 · FY2025 · CA
Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancer
$643,772Gang Lin · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Mechanisms controlling the persistence of infectious HIV reservoirs in children
$643,772Lisa M Frenkel · Seattle Children'S Hospital · R01 · FY2020 · HD
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reduction
$643,761Su-Hsin Chang · Washington University · U01 · FY2022 · CA
Population-based Assessment of Treatment Patterns and Outcomes among Women with Newly Diagnosed Ductal Carcinoma in Situ
$643,594Jean M Mitchell · Georgetown University · R01 · FY2017 · CA
Advancing Photoacoustic Tomography in breast imaging to predict response in breast cancers treated with neoadjuvant therapy
$643,569Lily Lau Lai · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions
$643,535David Spiegel · Stanford University · U01 · FY2015 · CA
The Role of Carboxypeptidase E in Cancer
$643,386Yoke P Loh · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD